A randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer.
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
Interventions: XELOX(or FOLFOX)+Bevacizumab is given until disease progression. Capecitabine (or LV5FU2)+Bevacizumab is given until disease progression. After progression, XELOX(or FOLFOX)+Bevacizumab is given until disease progression. Primary outcome(s): Time to Failure of Strategy Study Design: Parallel Randomized
创建时间：
2014-12-15
